BioSpace News Archive

Plus, what to do if your offer is paused and how to manage work anxiety.

Adcytherix SAS announced its incorporation and seed funding of € 30 million to develop novel antibody-drug- conjugates for the treatment of high unmet need diseases such as cancer.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will give a presentation at Stora Aktiedagarna in Stockholm on June 11-12.

Moberg Pharma AB has received subscription intentions, subscription commitments and top guarantee commitments totaling approximately SEK 113.5 million, related to the warrants of series 2023:1, from a few external professional investors and the Company’s largest shareholder, Östersjöstiftelsen.

Cantargia, announced the strengthening of its management team through the recruitment of Ton Berkien as Chief Business Officer.

InnoCare Pharma announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for the Company’s novel TYK2 inhibitor, ICP-332.

Biolog, Inc., a leading provider of cell-based microbial identification and phenotypic profiling products and services, is excited to announce the launch of its new PreBioM™ microplate product line for microbiome analysis and organism selection.

NMD Pharma A/S announces that it has dosed the first generalized myasthenia gravis patient in a Phase 2b clinical trial of NMD670, after receiving FDA IND clearance in March 2024 to conduct the study.

Viridian Therapeutics, Inc. reported details of its plans to initiate a phase 3 clinical trial program for its SC VRDN-003 product candidate for patients with moderate-to-severe TED.

The SURVEYOR Study met its primary endpoint demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery ( HD-CAB) composite score at baseline between healthy participants and participants with Huntington’s Disease (HD) prior to any treatment with dalzanemdor (SAGE-718) or placebo; further underscoring the cognitive impact of HD For participants with HD that received dalzanemdor or placebo, dalzanemdor was generally well-tolerated with no new